Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia

Abstract In this study, we compared intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) in terms of serum IgG concentration and incidence of infections in patients with hypogammaglobulinemia secondary to chemo-immunotherapy regimens including the anti-CD20 monoclonal antibody...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2016-05, Vol.166-167, p.103-104
Main Authors: Spadaro, Giuseppe, Pecoraro, Antonio, De Renzo, Amalia, Pepa, Roberta Della, Genovese, Arturo
Format: Article
Language:English
Subjects:
Agammaglobulinemia - blood
Agammaglobulinemia - chemically induced
Agammaglobulinemia - drug therapy
Aged
Allergy and Immunology
B-Lymphocytes - drug effects
B-Lymphocytes - pathology
Drug Administration Schedule
Female
Humans
Immunoglobulin G - blood
Immunoglobulins, Intravenous - administration & dosage
Immunoglobulins, Intravenous - therapeutic use
Immunologic Factors - adverse effects
Infusions, Intravenous
Infusions, Subcutaneous
Lymphoproliferative Disorders - blood
Lymphoproliferative Disorders - drug therapy
Male
Middle Aged
Rituximab - adverse effects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In this study, we compared intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) in terms of serum IgG concentration and incidence of infections in patients with hypogammaglobulinemia secondary to chemo-immunotherapy regimens including the anti-CD20 monoclonal antibody rituximab. Fourteen patients with a B-cell lymphoproliferative disease treated for at least six months with a rituximab-including chemo-immunotherapy regimen were recruited. Mean serum levels of IgG were higher during replacement therapy than at the end of rituximab treatment (p < 0.001). Moreover, serum IgG level was higher during replacement therapy with SCIG than with IVIG (p < 0.001). No differences in the incidence of infections were observed. Although the non-randomized design and the small number of patients do not allow definitive conclusions to be drawn, study results suggest that higher mean serum IgG levels are reached when using the subcutaneous route after a switch from the intravenous regimen, and that IVIG and SCIG offer comparable protection against infections.
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2016.04.001